The BRAFV600E mutation acts synergistically with TERT promoter mutations and the presence of both mutations is associated with greater cancer aggressiveness, lymph node and distant metastasis, advanced tumor stage, recurrence, and increased mortality in patients with PTC (33–35). This evidence concerns the gene TERT and neoplasm.